| ¿µ¹® | cell-mediated immunity | ÇÑ±Û | ¼¼Æ÷¸Å°³¸é¿ª |
|---|---|---|---|
| ¼³¸í | ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£ÇÏ´Â ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â ƯÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù. ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº ƯÁ¤ÇÑ ¹°Áú¿¡ °ü°èÇÏ´Â ¸é¿ªÀÌ ¾Æ´Ï¶ó ƯÁ¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö ÀÖ´Â ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀÎ °Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇÏ´Â ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀÇ È°µ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ ƯÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö ÀÖ´Â ¼¼Æ÷¸¦ »ý¼ºÇÏ°Ô ÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇÏ°Ô ÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | nerve cell | ÇÑ±Û | ½Å°æ¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | ½Å°æ¼¼Æ÷´Â ¿Ã¹Ù¸¥ ½Å°æÀü´ÞÀ» À§ÇÑ °¢ ºÎºÐº°·Î ³ª´µ¾îÁ® ÀÖ´Ù. ½Å°æ¼¼Æ÷¿¡¼´Â ÀüÇØÁ®¿À´Â ÀÚ±ØÀ» Àü±âÀûÀÎ ½ÅÈ£·Î ¹Ù²î¾î º¸³»°Å³ª ¹Þ°Ô µÈ´Ù. ÀÌ·± Àü±âÀûÀÎ Çö»óÀº °¢ ½Å°æ¼¼Æ÷³»¿¡ Á¸ÀçÇÏ´Â °¢ ÀÌ¿Âä³Î(ion channel: ionÀ̶õ ³ªÆ®·ý, Ä®·ý µîÀ» ÁöĪÇÏ´Â ¸»µé·Î½á, À̵éÀÌ ¼¼Æ÷¸·¿¡ ÀÇÇØ ³ª´µ¾îÁú ¶§ »ý±â´Â Àü¾ÐÂ÷°¡ Àü±âÀû ÀÚ±ØÀ» ÀÏÀ¸Å°°í À¯ÁöÇϴµ¥ °áÁ¤ÀûÀÎ ¿ªÇÒÀ» ÇÑ´Ù)µéÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ÀÌ·ç¾îÁö°Ô µÈ´Ù. |
||
| ¿µ¹® | glia cell | ÇÑ±Û | ¾Æ±³¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | ½Å°æ¼¼Æ÷ »çÀÌ¿¡¼ ±×¹°±¸Á¶¸¦ ÀÌ·ç¸ç À̸¦ ÁöÁöÇÏ´Â Á¶Á÷. ½Å°æ¾Æ±³¼¼Æ÷´Â ½Å°æ¸ð¼¼Æ÷¿Í °¥¶óÁø ¾Æ±³¸ð¼¼Æ÷°¡ ´Ù½Ã ¿©·¯ ÇüÅ·ΠºÐÈ-¼ºÀåÇÑ °ÍÀÌ´Ù. ³ú½ÇÀ̳ª ô¼öÁ߽ɰüÀÇ º®À» µ¤°í ¿øÁÖ»ó ¶Ç´Â ÀÔ¹æÇüÀ̸ç, Ãʱ⿡´Â À¯¸®¸é¿¡ ¼¶¸ð°¡ ÀÖ´Ù. ´ëÇü¼¼Æ÷´Â º°³ú½Ç¸·¼¼Æ÷´Â ¾Æ±³¼¼Æ÷¶ó°í Çϸç, ½Å°æ¼¼Æ÷³ª ½Å°æ¼¶À¯ »çÀÌ¿¡ »êÀçÇÑ´Ù. ±× ¿Ü¿¡ Èñ¼Òµ¹±â¾Æ±³¼¼Æ÷µµ Æ÷ÇԵȴÙ. |
||
| ¿µ¹® | reserve cell | ÇÑ±Û | ¿¹ºñ¼¼Æ÷ |
|---|---|---|---|
| ¼³¸í | ÀϹÝÀûÀ¸·Î »óÇÇÁ¶Á÷¿¡¼ ÀÌ¹Ì ÀÖ´ø »óÇǼ¼Æ÷°¡ ¼Õ»óÀ» ¹Þ¾Æ »ç¸êÇÏ¸é ¸Å²ãÁö´Â ±× ¹Ø¿¡ ÀÖ´Â ¹ÌºÐȼ¼Æ÷ ¿¹¸¦ µé¸é, ±â°üÁö ³»Ç¥¸éÀ» µ¤´Â ÁßÃþ ¿øÁÖ »óÇÇÀÇ ±âÀú¿¡ ÀÖ´Â ÀÛÀº ¹ÌºÐÈ »óÇÇ ¼¼Æ÷. |
||
| CFU-S, | CFUS colony-forming unit, spleen; colony-forming unit, stem cells |
|---|---|
| PFU | plaque-forming unit; pock-forming unit |
| AMA | against medical advice; alkaline membrane assay; American Management Association; American Medical A... |
| NA | Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida... |
| ACC | accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst... |
| Friend spleen focus forming virus | <virology> Defective virus found in certain strains of Friend virus, detected by its ability to form foci in spleens of mice and believed to be responsible in those strains for the production of a leukaemia associated with polycythaemia rather than anaemia. (18 Nov 1997) |
|---|---|
| lignin-forming peroxidase | <enzyme> Involved in polymerization of cinnamyl alcohols into lignin;amino acid sequence has been determined for tobacco enzyme Registry number: EC 1.11.1.- (26 Jun 1999) |
| antibody-dependent cell cytotoxicity | The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. (12 Dec 1998) |
| antibody producing cell | <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell. (18 Nov 1997) |
| antiparietal cell antibody | <immunology> A serologic blood test which measures the presence of antibodies to gastric parietal cells. Less than 2% of the general population will be antibody positive although this can be higher in the elderly. Approximately 90% of individuals with pernicious anaemia will be antibody positive. A positive result may also be seen in atrophic gastritis, gastric ulcer, thyroid disease, iron deficiency anaemia and diabetes. (13 Jan 1998) |
| cell-bound antibody | A term used for antibody on the surface of cells that may be bound either through antigen combining sites or other sites such as the Fc region. (05 Mar 2000) |
| T-cell-rich, B-cell lymphoma | <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component. See: adult T-cell lymphoma. (05 Mar 2000) |
| affinity antibody | The measure of the interaction between molecules such as a receptor and its ligand. This interaction is reversible. (05 Mar 2000) |
| agglutinating antibody | 1. An antibody that causes clumping or agglutination of the bacteria or other cells which either stimulated the formation of the agglutinin, or contain immunologically similar, reactive antigen. Synonym: agglutinating antibody, immune agglutinin. 2. A substance, other than a specific agglutinating antibody, that causes organic particles to agglutinate, commonly qualified, e.g., plant agglutinin. (05 Mar 2000) |
| anaphylactic antibody | Antibody that has an affinity for certain kinds of cells, in addition to and unrelated to its specific affinity for the antigen that induced it, because of the properties of the Fc portion of the heavy chain. See: heterocytotropic antibody, homocytotropic antibody, cytotropic antibody test. Synonym: anaphylactic antibody, cytophilic antibody. (05 Mar 2000) |
| anti-basement membrane antibody | Autoantibodies to renal glomerular basement membrane antigens. (05 Mar 2000) |
| antibody | An immunoglobulin molecule that has a specific amino acid sequence by virtue of which it interacts only with the antigen that induced its synthesis in cells of the lymphoid series (especially plasma cells) or with antigen closely related to it. Antibodies are classified according to their ode of action as agglutinins, bacteriolysins, haemolysins, opsonins, precipitins, etc. (18 Nov 1997) |
| antibody affinity | A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. (12 Dec 1998) |
| antibody aldolase | <enzyme> Prepared by reactive immuninization to catalyze a wide variety of aldol reactions and decarboxylations Registry number: EC 4.1.2.- Synonym: fab 33f12, aldolase catalytic antibody (26 Jun 1999) |
| antibody-coated bacteria test, urinary | Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|